Clinical Trial Update: A Phase 1 Study of ESG206 in Adult Subjects With B-cell Lymphoid Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 trial of ESG206 in adults with B-cell lymphoid malignancies has completed. The study status indicates completion with safety and early activity data a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoid Malignancies

Drugs mentioned

• ESG206

Snippet

Sponsor: Shanghai Escugen Biotechnology Co., Ltd | Conditions: B-cell Lymphoid Malignancies | Phase 1 | Status: COMPLETED